Early-stage breast cancer (BC) patients with hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2−) disease are classically treated with surgery, followed by adjuvant endocrine therapies with or without adjuvant chemotherapy (CT) and radiation treatment. This evidence concerns the gene NR4A1 and breast carcinoma.